Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 26;6(7):FSO583.
doi: 10.2144/fsoa-2020-0034.

ITGA4 gene methylation status in chronic lymphocytic leukemia

Hanaa Rm Attia  1 , Mona Hamed Ibrahim  1 , Shereen H Abd El-Aziz  1 , Naglaa M Hassan  2 , Randa A Osman  3 , Heba A Hagag  4 , Marianne E Yassa  5 , Amany H Abdelrahman  6 , Iman I Salama  7 , Mohamed Emam Sobeih  8
Affiliations

ITGA4 gene methylation status in chronic lymphocytic leukemia

Hanaa Rm Attia et al. Future Sci OA. .

Abstract

Background: We aimed to investigate ITGA4 gene expression pattern and to explore its methylation heterogeneity in chronic lymphocytic leukemia (CLL).

Patients & methods: Eighty one CLL patients and 75 healthy subjects were enrolled and prognostic evaluation of patients was assessed. ITGA4 q-realtime PCR was performed using Applied Biosystems, TaqMan gene expression assay. ITGA4 gene-specific CpG methylation was investigated in real time using pyrosequencing technology.

Results: ITGA4 was differentially expressed in CLL patients. The CpG sites-1, 2 and 3 showed significantly higher mean levels than healthy controls (p = <0.001, 0.007 and 0.009). Significant association between CpG site-1 and CLL has been detected using age-adjusted logistic regression (p < 0.001).

Conclusion: Hypermethylation at ITGA4 gene CpG sites (1,2,3) is a characteristic feature in CLL.

Keywords: ITGA4 gene expression; beta 2 microglobulin; chronic lymphocytic leukemia; cytogenetics; methylation analysis; prognostic markers; pyrosequencing.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors gratefully acknowledge the financial support of the Science and Technology Development Fund (STDF), Egypt through Targeted Health call grant no. 22918 and Capacity Building Grant no. 4880. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. ITGA4; genomic location.
ITGA4 gene specification and chromosome location according to GeneGlobe specification, [21].
Figure 2.
Figure 2.. ITGA4 gene methylation (%) of the four CpG sites by pyrosequencing of some chronic lymphocytic leukemia patients.
Figure 3.
Figure 3.. Comparison between ITGA4 gene methylation (%) of the four CpG sites by pyrosequencing between chronic lymphocytic leukemia patients (n = 81) and controls (n = 75).
The CpG sites-1,2,3 showed significantly higher mean levels in chronic lymphocytic leukemia patients than healthy controls (p = <0.001, 0.007 and 0.009, respectively). Error bars: 95% CI.
Figure 4.
Figure 4.. Receiver operating characteristics curves for the ITGA4 methylation % of the four CpG sites among patients and healthy controls.
ROC: Receiver operating characteristics.
Figure 5.
Figure 5.. Comparison between ITGA4 gene methylation (%) of the four CpG sites by pyrosequencing between different groups of chronic lymphocytic leukemia patients based on B2M levels (patients with B2M >3.5 µg/ml, n = 62; patients with B2M <3.5 µg/ml, n = 19).
Error bars: 95% CI.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stilgenbauer S, Schnaiter A, Paschka P. et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 123(21), 3247–3254 (2014). - PubMed
    1. Landau DA, Tausch E, Taylor-Weiner AN. et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526, 525–530 (2015). - PMC - PubMed
    1. Rassenti LZ, Huynh L, Toy TL. et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N. Engl. J. Med. 351(9), 893–901 (2004). - PubMed
    1. Bulian P, Shanafelt TD, Fegan C. et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J. Clin. Oncol. 32(9), 897–904 (2014). - PMC - PubMed

    2. • In this analysis of approximately 3000 patients with chronic lymphocytic leukemia (CLL), authors identified CD49d as the strongest flow cytometry-based predictor of overall survival (OS) and treatment-free survival (TFS) independent of CD38 and ZAP-70.

    1. Zucchetto A, Caldana C, Benedetti D. et al. CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for methylation-dependent regulation mechanism. Blood 122(19), 3317–3321 (2013). - PubMed

    2. • Authors demonstrated that CD49 is universally expressed in Trisomy12 CLL and is regulated by a methylation-dependent mechanism